BioSpace News Archive

Castellum, Inc. (ONOV:OTC) announces strong revenue and record quarterly EBITDA for the second quarter ended June 30, 2020. The Company expects to file its 2020 Q2 report at www.otcmarkets.com within the next 10 days. Castellum’s financial picture continues to grow stronger. Revenue for Q2 2020 was $3.4 million. EBITDA, a non-GAAP measure, was over $550,000. Cash on hand at quarter end was over $1.9 million (up from $1.1 million at the en

AxoProtego Therapeutics (AxoProtego) has announced that it has licensed a novel investigational therapy for patients with chemotherapy-induced peripheral neuropathy (CIPN). Currently, there is a large unmet medical need for this life-altering condition as 30-80% of cancer patients develop chemotherapy-induced peripheral neuropathy

Luminare announced today that the company is proud to partner with the CDC on the “Taking America Back to Work” showcase for the NACCHO Conference, which took place July 7-9, 2020 . Quickscreen by Luminare is a confidential, highly scalable and secure online self-certification platform designed for businesses of all types and sizes -- e

Incorporating satellite observations in disease models has become a valuable component in informing public health policy and decisions.

Elevar Therapeutics, Inc. (“Elevar”), a late-stage biopharmaceutical company focused on developing and commercializing promising therapies to address unmet needs in cancer, and Tanner Pharma Group (“Tanner”), a global provider of integrated specialty access solutions, today announced a partnership that will facil

OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral DNA–based cancer immunotherapies, today announced that Kellie Malloy Foerter , previously Chief Clinical Development Officer, has been appointed Chief Operating Officer, effective immediately. W

Heritage Global Inc. (OTCQB: HGBL, CSE: HGP) (“Heritage Global,” “HGI” or “the Company”), an asset services company specializing in financial and capital assets, today announced results from its ongoing monthly Pharmaceutical Sector Sale for July.

Apic Bio, Inc. today announced the formation of its Scientific Advisory Board (SAB) which includes internationally recognized gene therapy experts. The SAB will provide clinical and scientific expertise to help the Company advance its pipeline and leverage its proprietary silence and replace THRIVE™ platform. Apic’s CEO, John Reilly, MS/MBA, stated, “As we continue to advance our programs, it is critical tha

WhizAI, the first and only purpose-built cognitive insights platform for the life sciences, announces $4 million in seed funding led by Healthy Ventures, with participation from Bling Capital, Firebolt Ventures and existing investors.

Mitopure™, a first-of-its kind cellular nutrient, clinically proven to boost cellular function and improve muscle strength, is now available to health-striving consumers in Timeline Nutrition products*.